CFF Therapeutics Development Network Coordinating Center, Department of Pediatrics, Seattle Children's Research Institute, Seattle, Washington.
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine and Pediatrics, University of Washington School of Medicine, Seattle, Washington.
Semin Respir Crit Care Med. 2019 Dec;40(6):792-803. doi: 10.1055/s-0039-1697975. Epub 2019 Oct 28.
With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective cystic fibrosis transmembrane conductance regulator therapy, the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is an acute pulmonary exacerbation. Clinical and microbial epidemiology studies of CF pulmonary exacerbations continue to provide important insight into the disease course, prognosis, and complications. This work has now led to a number of large scale clinical trials with the goal of improving the treatment paradigm for CF pulmonary exacerbation. The primary goal of this review is to provide a summary of the pathophysiology, the clinical epidemiology, microbial epidemiology, outcome and the treatment of CF pulmonary exacerbation.
随着囊性纤维化 (CF) 患者生存率的提高和高效囊性纤维化跨膜电导调节剂治疗的出现,这种复杂的多系统疾病的临床谱仍在不断发展。在 CF 患者的病程中,对 CF 患者最重要的临床事件之一是急性肺部恶化。对 CF 肺部恶化的临床和微生物流行病学研究继续为疾病过程、预后和并发症提供重要的见解。这项工作现在已经导致了一些大型临床试验,目的是改善 CF 肺部恶化的治疗模式。本文的主要目的是总结 CF 肺部恶化的病理生理学、临床流行病学、微生物流行病学、结局和治疗。